Muhammed H. Rahaman

Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation

Solomon Tadesse, Mingfeng Yu, Laychiluh Mekonnen et al. · Journal of Medicinal Chemistry · 2017 · 68 citations · Full text

Chemoprevention Strategy, Pharmacotherapy, Cell Cycle +17

Targeting CDK9 for treatment of colorectal cancer

Muhammed H. Rahaman, Frankie Lam, Long‐Jin Zhong et al. · Molecular Oncology · 2019 · 56 citations · Full text

CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia

Muhammed H. Rahaman, Yingyi Yu, Long‐Jin Zhong et al. · Investigational New Drugs · 2018 · 39 citations

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +10

Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia

Sarah Diab, Ahmad M. Abdelaziz, Peng Li et al. · European Journal of Medicinal Chemistry · 2017 · 24 citations · Full text

Hematological Malignancy, Dual Inhibition, Medicine +11

Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation

Mingfeng Yu, Theodosia Teo, Yuchao Yang et al. · European Journal of Medicinal Chemistry · 2021 · 18 citations · Full text

Medicinal Chemistry, Pharmaceutical Science, Structure-activity Relationship Analysis +11